Can a Patient Take Paxlovid and Bupropion Concurrently?
No, concurrent use of Paxlovid (nirmatrelvir/ritonavir) and bupropion requires significant dose adjustment of bupropion due to a clinically significant drug-drug interaction, and you must carefully weigh whether the COVID-19 treatment benefit outweighs the complexity of managing this interaction.
Understanding the Drug Interaction
The ritonavir component of Paxlovid is a strong CYP3A inhibitor that paradoxically induces CYP2B6, the primary enzyme responsible for bupropion metabolism 1. This creates a problematic interaction:
- Ritonavir 600 mg twice daily reduces bupropion exposure by 62-67% (both AUC and Cmax) 2
- Ritonavir 100 mg twice daily (the dose in Paxlovid) reduces bupropion exposure by 21-22% 2
- The active metabolite hydroxybupropion is also significantly reduced (31-50% decrease) 3
This means bupropion becomes substantially less effective when taken with Paxlovid, potentially leading to loss of therapeutic effect for depression, smoking cessation, or other indications.
Clinical Decision Algorithm
Step 1: Assess COVID-19 Treatment Necessity
- Is the patient at high risk for COVID-19 progression (hospitalization/death)?
- Are symptoms within 5 days of onset?
- If YES to both → Paxlovid has strong evidence for benefit 4, 5
- If NO → Consider alternative COVID-19 treatments or no antiviral treatment
Step 2: Evaluate Bupropion Indication Urgency
- For depression/psychiatric indications: Can bupropion be temporarily discontinued for 5 days without significant risk?
- For smoking cessation: This is typically non-urgent and can be interrupted
- For seizure risk: Note that bupropion lowers seizure threshold; temporary discontinuation may actually reduce risk during acute illness
Step 3: Management Options
Option A - Preferred if COVID-19 treatment is indicated:
- Discontinue bupropion before starting Paxlovid
- Complete the 5-day Paxlovid course
- Wait at least 3-5 days after completing Paxlovid before restarting bupropion (to allow ritonavir washout)
- Resume bupropion at previous dose
Option B - If bupropion cannot be discontinued:
- Consider alternative COVID-19 treatments without this interaction:
- Only use Paxlovid with continued bupropion if COVID-19 risk clearly outweighs psychiatric risk
Option C - If both drugs must continue (NOT recommended):
- Increase bupropion dose up to 100% to compensate for reduced exposure 2, 3
- Do NOT exceed maximum recommended daily dose of bupropion (450 mg/day for immediate release, 400 mg/day for sustained release, 450 mg/day for extended release) 2
- Monitor closely for loss of bupropion efficacy
- Return to baseline bupropion dose 3-5 days after completing Paxlovid
Critical Safety Considerations
FDA Black Box Warning
The FDA label explicitly warns that ritonavir may lead to potentially severe, life-threatening, or fatal events from drug interactions 1. While bupropion interaction is not life-threatening in the traditional sense, loss of antidepressant efficacy carries psychiatric risks.
Common Pitfalls to Avoid
- Do not simply continue both medications without adjustment - this will result in subtherapeutic bupropion levels
- Do not exceed maximum bupropion doses even when compensating for the interaction - seizure risk increases
- Do not restart bupropion immediately after Paxlovid - ritonavir has a prolonged effect lasting several days after discontinuation 5
- Do not forget to counsel the patient about temporary loss of smoking cessation or antidepressant effect
When to Seek Expert Consultation
Contact clinical pharmacology if 6:
- Patient has complex psychiatric history where bupropion interruption poses significant risk
- Patient is on multiple interacting medications
- Uncertainty exists about the risk-benefit balance
Evidence Quality Note
The interaction data comes from well-designed pharmacokinetic studies in healthy volunteers 2, 3, and the FDA label explicitly addresses ritonavir's role as a "perpetrator of many drug-drug interactions" 1. French pharmacology guidelines classify this as requiring careful management 6. The evidence is clear and consistent: this interaction is real, dose-dependent, and clinically significant.
Practical Implementation
For a typical patient on bupropion 150 mg twice daily who develops COVID-19:
- Stop bupropion on day 1
- Start Paxlovid on day 1 (if within 5 days of symptoms and high-risk)
- Complete 5-day Paxlovid course
- Wait until day 9-10 post-COVID diagnosis
- Restart bupropion 150 mg twice daily
Document the plan clearly and ensure patient understands the temporary medication change and its rationale.